Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
47.45 ^USD	+0.83%		-5.33%	-21.14%

Apr. 23	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
Apr. 22	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Evolution of the average Target Price on Legend Biotech Corporation

Price target over the last 5 years

History of analyst recommendation changes

0e9a7.ZAyMRAUdDNHe0pwn5L5I8XmMbEHr9oLC0OUSq14Qks8.BnbmETR3aOSWuKVv1s4XvDzJOBK5k_GosrBx3mpKpJpSX95zfS9H5eeL1Q~871ce5dd0deccde15df6903316ed1e68

Analyst Recommendations on Legend Biotech Corporation

Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	Apr. 17	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	Apr. 03	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	Mar. 18	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	Mar. 13	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	Jan. 03	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	Dec. 19	MT
Earnings, Interest Rates Cap Wall Street Pre-Bell; Asia Choppy, Europe Up	Nov. 20	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	23-07-21	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	23-07-21	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	23-07-20	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	23-06-13	MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating	23-06-06	MT
William Blair Initiates Legend Biotech at Market Perform	23-05-25	MT
Daiwa Securities Initiates Legend Biotech at Buy Rating	23-05-22	MT
Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating	23-05-19	MT
RBC Boosts Price Target on Legend Biotech to $83 From $74, Cites Greater Confidence in Manufacturing Progress, Keeps Outperform Rating	23-05-19	MT
BMO Capital Adjusts Price Target on Legend Biotech to $90 From $79, Maintains Outperform Rating	23-04-25	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $77 From $66, Maintains Buy Rating	23-04-20	MT
BTIG Adjusts Price Target on Legend Biotech to $85 From $75, Maintains Buy Rating	23-04-20	MT
JPMorgan Adjusts Price Target on Legend Biotech to $76 From $65, Maintains Overweight Rating	23-04-19	MT
RBC Capital Lifts Legend Biotech Price Target to $74 From $73, Maintains Outperform Rating	23-04-06	MT
UBS Adjusts Legend Biotech's Price Target to $76 From $66, Maintains Buy Rating	23-01-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

47.45 USD

Average target price

86.33 USD

Spread / Average Target

+81.94%

High Price Target

95 USD

Spread / Highest target

+100.21%

Low Price Target

65 USD

Spread / Lowest Target

+36.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Legend Biotech Corporation

Scotiabank
Cantor Fitzgerald
UBS
Raymond James
RBC Capital Markets
HC Wainwright
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim

Ratings for Legend Biotech Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar